AGRP Genotype

Some people feel hungry constantly. Others can skip meals without thinking about it. A small but real piece of that difference traces back to a single gene in your brain's appetite circuitry, and you can now check which version of it you inherited.

AGRP (agouti-related peptide) is a brain signal that turns hunger on. It works mainly by blocking a receptor called MC4R that would otherwise tell you to stop eating, and the neurons that release it also release other hunger-promoting signals. The AGRP gene is the blueprint for making that signal, and small spelling differences in this gene have been linked in human studies to anorexia nervosa risk, late-onset weight gain, food preferences, and diabetes risk. This is a research-grade genetic test, not a routine clinical screen, but it gives you a baseline read on a hidden piece of your appetite biology.

What This Gene Actually Does

AGRP is one of several genes that act as central regulators of how much you want to eat. Variants in this gene, particularly in its protein-coding region and in the region that controls how strongly the gene gets switched on, have been studied for their links to appetite, body fat, and metabolic disease in humans. The effects on any individual person are usually small, because body weight and eating behavior are shaped by many genes plus environment. But AGRP appears repeatedly in the research as one contributing piece.

The two most studied spots in the AGRP gene are a coding change called Ala67Thr (also written rs5030980) and a promoter change at position -38 (written -38C>T). A rarer promoter change called +79G>A has also been described in a small number of carriers and reduced gene activity in lab cells. Each variant has been associated with a different mix of traits, and findings have not always pointed in the same direction across populations, which is why interpretation is more nuanced than a simple high-or-low result.

Anorexia Nervosa Risk

One of the earliest signals in the AGRP literature is a link with anorexia nervosa. In a study that screened 100 patients with anorexia nervosa and then tested 45 additional patients alongside 244 controls, two AGRP variants that always travel together were found in about 11% of patients compared with about 4.5% of controls, suggesting these AGRP variants may raise susceptibility to the disorder, possibly by blunting the brain's normal hunger drive.

This finding has not always replicated. A later study of 745 anorexia nervosa patients found no significant differences in AGRP variant frequency between patients and controls, although one AGRP variant tracked with the lowest body weight reached during illness. The overall picture is a possible but uncertain contribution rather than a settled risk factor. Carrying these variants does not mean you will develop anorexia nervosa. Most carriers do not. But if you have a personal or family history of restrictive eating, low body weight, or difficulty feeling hunger, this test can add one piece of biological context to that picture.

Late-Onset Obesity and Leanness

The Ala67Thr variant has been linked to a curious age-dependent pattern with body fat. In adults around age 25, the variant showed no clear effect on weight or body composition. But in their parents, with an average age of 53, the G/G genotype was significantly associated with higher overall fatness and more belly fat. This suggested AGRP variation may matter more for weight as you age, perhaps when other defenses against weight gain weaken.

The story is not one-directional. A separate study found that homozygous carriers of the Thr67 variant were leaner, not heavier, and another study in a Latvian population found no association with BMI at all. A larger analysis of about 2,000 European Americans that tested 30 obesity-related genes did find the Ala67Thr variant significantly associated with BMI, although the size of the effect was modest. Taken together, Ala67Thr appears to nudge body weight in ways that depend on age, ancestry, and other genes, rather than acting as a clean risk or protective variant.

Diabetes Risk and Body Weight

In a study of 538 West Africans, the -38C>T promoter variant in AGRP was linked to both lower body weight and lower diabetes risk. Women carrying two copies of the T version had significantly lower BMI, and men with at least one T copy were over two times less likely to have diabetes than men without it. An earlier study in people of African ancestry, however, reported the opposite direction, with the C/C genotype linked to higher BMI and type 2 diabetes. The -38C>T variant clearly sits near metabolic disease risk, but the direction and size of the effect have differed between studies and have not been replicated across all ancestries.

Food Preferences

AGRP variants have also been tied to what you tend to eat, not just how much. In a study of about 750 adults, white participants who carried one copy of the Ala67Thr variant got a smaller share of their energy from fat and about 2.6% more from carbohydrates than non-carriers. In Black participants, the -38C>T promoter variant was tied to protein intake, with T/T homozygotes eating less protein. These are small but real shifts in macronutrient preference, suggesting AGRP genotype nudges food choice in ways that may compound over years.

Why Findings Vary by Ancestry

Different AGRP variants are common in different populations. The Ala67Thr coding variant shows up more often in studies of European-ancestry adults, while the -38C>T promoter variant has been studied most in West African populations. This is one reason that the same test result can carry slightly different meanings depending on your background. It is also why broad genetic panels that draw on European reference data may miss or misjudge effects in people of other ancestries.

This is not a contradiction in the science. It is the normal pattern for common genetic variants. AGRP is one contributory gene within a larger polygenic and environmental network that shapes body weight and eating behavior, and any single variant explains only a small fraction of the difference between individuals.

A One-Time Test

Your AGRP genotype is fixed from birth and does not change with age, weight, diet, illness, or treatment. There is no reason to repeat this test once you have a reliable result. The value of the test is not in retesting it, but in using your result to inform decisions over the coming decades.

Where serial testing does matter is in the downstream measures this genotype touches. If you are a carrier of a variant linked to higher BMI or diabetes risk, the right cadence is to track standard metabolic markers more aggressively. A reasonable rhythm is fasting glucose, HbA1c, and a full lipid panel at least once a year, with weight and waist trends checked more often. If you carry a variant linked to lower body weight and restrictive eating patterns, the trending priority shifts toward nutritional markers, bone density when relevant, and conversations with a clinician familiar with eating behavior.

When Results Can Be Misleading

Genetic tests do not have the same confounders as blood biomarkers, but they do have their own limits. A few are worth knowing:

• Limited variant coverage: this test reports specific AGRP variants. A result showing none of the known variants does not rule out other rare changes in the AGRP gene that the assay was not designed to detect.
• Ancestry-specific meaning: the same variant can carry different risk weights in different ancestral populations, and some AGRP studies have reported opposite directions of effect across groups. A result interpreted against European reference data may not apply equally to someone of African, East Asian, or Indigenous ancestry.
• Variants of uncertain significance: occasionally a test detects a change in the gene that has not yet been well studied. The lab may report it, but no one can tell you yet what it means clinically.
• Direct-to-consumer reports: if you have seen an AGRP-related result from a consumer genomics report, the variant coverage and analytical accuracy may differ from a clinical-grade test. Confirmation by a clinical lab is appropriate before acting on a consumer result.

What to Do With an At-Risk Result

If you carry an AGRP variant linked to higher body weight or diabetes risk, the practical move is not to do something about the gene itself. The gene cannot be changed. The move is to take the things that already protect against weight gain and metabolic disease more seriously, and to monitor more often. Annual fasting glucose, HbA1c, and a lipid panel give you the running data. Adding ApoB, hs-CRP, and a fasting insulin gives you a much sharper read on early metabolic drift than glucose alone.

If you carry a variant that has been associated with anorexia nervosa susceptibility, the action is different. Eating disorder risk is not something a blood panel will catch, and the genetic link itself is unsettled. The pathway is to share the result with a clinician familiar with eating behavior, and to use it as one signal among several, not as a diagnosis. Most carriers will never develop anorexia. The result is a possible risk factor, not a fate.

For most people, the right next step is a baseline conversation with a clinician who can put this result in the context of your family history, your current weight and eating patterns, and your broader metabolic risk picture. A genetic counselor is appropriate if multiple genetic results are coming in at once or if you want help thinking through implications for biological relatives.